Overview of Ганфорт

Quick Facts

Property	Description
Active Ingredients	Bimatoprost and Timolol maleate
Form	Sterile Ophthalmic Solution (Eye Drops)
Pharmacological Class	Prostaglandin Derivative and Beta-Blocker Combination
Common Use	Reduction of Elevated Intraocular Pressure (IOP)
Origin	Synthetic Compounds

The Fixed-Dose Combination: Definition and Pharmacological Class

Ганфорт (Ganfort) is a prescription-only, synthetic fixed-dose combination (FDC) ophthalmic preparation classified as an ocular hypotensive agent. Its pharmacological classification places it within the high-level group of antiglaucoma preparations, specifically combining a prostaglandin derivative and a beta-blocker. This FDC approach is clinically recognized as a potent means of controlling abnormally high fluid pressure inside the eye for managing pressure.

Composition and Pharmaceutical Form of Ганфорт

The medication is composed of two primary active ingredients: Bimatoprost and Timolol maleate. Bimatoprost is a synthetic prostaglandin analog, while Timolol maleate functions as a synthetic non-selective beta-adrenergic receptor antagonist. Ганфорт is formulated as a sterile ophthalmic solution delivered as eye drops in an aqueous solution base, designed for accurate topical ocular administration. The presentation of this FDC specifically as a solution for topical application highlights its focus on adult patients requiring convenient and consistent management of their eye pressure.

General Purpose of the Combination Therapy

The general purpose of Ганфорт is to facilitate a powerful and sustained reduction of elevated intraocular pressure (IOP). The two active compounds exhibit a beneficial synergistic action, meaning their combined pressure-lowering effect significantly exceeds what either ingredient could achieve separately. Bimatoprost enhances the rate of fluid drainage from the eye, and Timolol concurrently reduces the speed of internal fluid formation, providing a robust, dual-pathway method for long-term eye pressure management.

What side effects are possible with Ганфорт?

Possible side effects and safety information

The official safety profile for the Bimatoprost and Timolol maleate fixed-dose combination (Ганфорт) classifies potential adverse reactions by frequency and the body system affected, based on regulatory documentation.

Frequency-Classified Adverse Reactions

Classification	Examples of Documented Reactions
Very Common	Ocular Hyperaemia (eye redness).
Common	Ocular pruritus (eye itching), eye stinging or burning, Conjunctivitis, dry eye, eye pain, Headache.
Uncommon	Dizziness, Corneal erosion, Eyelid oedema (swelling), Increased iris pigmentation.
Frequency Not Known	Macular oedema, Uveitis, Bradycardia (slow heart rate), Asthma.

Systemic and Serious Safety Considerations

Adverse reactions are classified into System Organ Classes (SOCs), including Eye Disorders, Nervous System Disorders, Cardiac Disorders, and Respiratory/Thoracic Disorders. The Timolol component is a beta-blocker, and its systemic absorption introduces specific safety constraints.

Serious adverse reactions documented in regulatory sources include systemic effects consistent with beta-blockade, such as Bradycardia and severe respiratory reactions like Asthma exacerbation. Specific ocular conditions, including Macular Oedema and Uveitis, are also officially listed as possible adverse reactions.

Safety-related restrictions strictly contraindicate the use of this medicine in individuals with certain severe pre-existing health conditions. These include bronchial asthma (or a history of it), severe chronic obstructive pulmonary disease (COPD), and certain serious cardiac conditions such as overt cardiac failure, sinus bradycardia, or second or third-degree atrio-ventricular block (without a pacemaker).

Finally, the regulatory safety profile notes that the occurrence of Ocular Hyperaemia may be officially reduced with continued treatment. Documented long-term local effects may include darkening of the eyelid skin and changes to the length, thickness, or number of eyelashes.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this ophthalmic solution is officially noted by regulators as unlikely following appropriate topical ocular administration. However, the active component, Timolol maleate, can be systemically absorbed, and an overdose scenario is defined by the potential for systemic beta-blockade.

Documented Manifestations and Severe Outcomes The officially documented manifestations of an overdose primarily include signs associated with beta-blockade, such as bradycardia (slowed heart rate), hypotension (low blood pressure), and bronchospasm. Due to the systemic effects of Timolol, the regulatory labels identify the potential for severe or life-threatening outcomes. These documented outcomes include cardiac arrest and death associated with cardiac failure or severe bronchospasm.

When to Seek Immediate Medical Attention Given the documented potential for life-threatening cardiac and respiratory events, immediate medical attention must be sought if an overdose is suspected, for example, following accidental ingestion or excessive exposure.

Required Emergency Actions Regulatory documents specify that if an overdose occurs, the required course of action is symptomatic and supportive treatment. No specific antidote for the combination product is documented in the official prescribing information. In cases of accidental ingestion, procedures such as gastric lavage should be considered. Due to the risk of severe events, hospital monitoring is necessary for continued observation of systemic effects. Regulatory notes also indicate that the Timolol component does not dialyse readily.

Therapeutic Uses of Ганфорт

Therapeutic Purpose

Ganfort is a combination ophthalmic solution used to reduce elevated intraocular pressure (IOP) in patients where single-agent therapies have not achieved sufficient results. By lowering fluid pressure within the eye, the medication helps manage conditions that can lead to progressive vision loss.

Conditions Treated

The medication is primarily indicated for the following conditions:

Open-Angle Glaucoma: A chronic condition where fluid does not drain properly from the eye, leading to increased pressure that can damage the optic nerve.
Ocular Hypertension: A state where the internal pressure of the eye is higher than the normal range, increasing the risk of developing glaucoma.

Mechanism of Action and Benefits

Ganfort utilizes two distinct physiological pathways to manage eye pressure effectively. This dual-action approach provides several clinical benefits:

Reduced Aqueous Humor Production: One component of the medication works to decrease the volume of fluid produced inside the eye.
Enhanced Fluid Outflow: The second component improves the drainage of fluid through the eye's natural outflow channels (the uveoscleral route).
Consistent Pressure Control: The combination of these two mechanisms often results in a more significant reduction in intraocular pressure than can be achieved by using either component individually.
Long-Term Maintenance: By maintaining stable pressure levels, the medication helps protect the optic nerve from the damage typically associated with prolonged ocular hypertension.

Eligibility and Restrictions for Use

The eligibility for using Ганфорт (Bimatoprost/Timolol) is strictly defined by regulatory authorities and is limited to adult patients (including the elderly) with open-angle glaucoma or ocular hypertension. Use is defined by specific conditions and absolute prohibitions, primarily due to the systemic absorption of the beta-blocker component.

Contraindicated Populations (Absolute Non-Eligibility)

Condition	Regulatory Status
Respiratory Disease (Asthma, Severe COPD)	Contraindicated
Cardiac Conditions (Severe Heart Block, Cardiac Failure, Cardiogenic Shock)	Contraindicated
Hypersensitivity to any component	Contraindicated

Age, Reproductive, and Conditional Restrictions

Population Group	Eligibility Status
Children and Adolescents (under 18 years)	Not Recommended (Safety/Efficacy Not Established)
Pregnancy	Should not be used unless clearly necessary
Lactation (Breastfeeding)	Should not be used
Hepatic or Renal Impairment	Caution (Not Studied)

The medicine is also restricted and requires caution in patients with mild/moderate COPD, labile diabetes, specific cardiovascular disease, and those at risk for macular oedema or active ocular inflammation. The medicine has not been studied in patients with conditions like neovascular or angle-closure glaucoma.

What should I know about interactions with other medicines?

GANFORT (bimatoprost/timolol) eye drops contain timolol, a beta-blocker, which can be absorbed into the bloodstream. This means that interactions similar to those seen with systemic beta-blocker medications are possible, potentially affecting the heart rate and blood pressure.

It is essential to inform your doctor about all medicines, supplements, or herbal products you are taking, especially before starting GANFORT. This is critical for patients with cardiovascular conditions or diabetes.

Key Potential Drug Interactions

Type of Medicine	Potential Interaction (Additive Effects)
Other Ophthalmic Beta-Blockers	Concurrent use is generally not recommended, as it may increase the risk of systemic side effects without greater IOP reduction.
Oral Beta-Blockers	Increased risk of low heart rate (bradycardia), low blood pressure (hypotension), and other systemic beta-blockade effects.
Heart/Blood Pressure Medicines	Calcium channel blockers, anti-arrhythmics (e.g., amiodarone, digitalis), and guanethidine may cause additive effects leading to marked bradycardia and/or hypotension.
CYP2D6 Inhibitors	Medicines like quinidine, fluoxetine, and paroxetine (used for depression) can potentially increase timolol concentrations and potentiate its effects.
Other Prostaglandin Analogues	Using other eye drops containing prostaglandin analogues (like latanoprost or travoprost) may decrease the intraocular pressure-lowering effect of GANFORT.
Antidiabetic Agents	Beta-blockers may mask the signs and symptoms of low blood sugar (hypoglycemia), requiring careful monitoring in diabetic patients.

Mechanism of Action

The Dual Mechanism: Inflow Suppression and Outflow Enhancement

Ганфорт works through two distinct, complementary pharmacodynamic mechanisms that modulate the fluid dynamics of the eye, leading to a reduction in intraocular pressure (IOP). This dual action simultaneously targets fluid generation and fluid clearance, resulting in a synergistic physiological effect.

Bimatoprost: Facilitating Uveoscleral Drainage

The bimatoprost component operates as a prostamide analogue, selectively engaging specific prostanoid receptors in ocular tissues. This receptor activation initiates a signaling cascade that promotes the relaxation and structural remodeling of the extracellular matrix within the ciliary muscle. This mechanism increases the permeability and efficiency of the uveoscleral outflow pathway, thereby facilitating the clearance of aqueous humor. The increased fluid egress contributes to a reduction in the overall fluid volume.

Timolol: Inhibiting Aqueous Humor Production

The timolol component operates within the beta-adrenergic receptor blockade domain. It acts as a non-selective antagonist on beta1 and beta2 receptors located in the ciliary body epithelium. This interference with catecholamine-mediated signaling suppresses the active secretory processes of the epithelium, resulting in the inhibition of aqueous humor formation. The reduced rate of fluid generation contributes to the overall effect on intraocular pressure.

Dosage and Administration Information

How to Use Ганфорт: Administration Guidelines

The following instructions describe the method for the administration of Ганфорт (Ganfort).

Administration Scope

Attribute	Instruction
Route of Administration	Topical Ophthalmic Administration (Eye Drops) directly to the affected eye(s).
Dosing Schedule	One drop in the affected eye(s). Administration must not exceed once daily.
Timing	Once daily, preferably at the same time each morning or evening.

Key Procedural Instructions

Correct administration involves specific steps to ensure proper local delivery and reduce systemic absorption:

Contact Lenses: Soft contact lenses must be removed prior to instillation. Reinsertion should be delayed by at least 15 minutes.
Missed Dose: If a dose is missed, the user should continue with the next scheduled dose. A double dose must not be instilled to compensate.
Concomitant Eye Drops: Any other topical ophthalmic products must be applied at least 5 minutes apart from Ганфорт.
Absorption Control: To help limit the drug's absorption outside the eye, it is advised to use nasolacrimal occlusion (closing the eyelids for 2 minutes or pressing on the tear duct) immediately following instillation.
Contamination: The container tip must not touch the eye, eyelids, or any other surfaces.

Population-Specific Rules

Adults (including the Elderly): The standard one-drop daily dose applies; no adjustment is required.
Pediatric Use (0–18 years): Use is not recommended, as safety and efficacy have not been established in this age group.

These instructions define the standardized protocol for using the medication to ensure consistency in administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Ганфорт (Bimatoprost/Timolol)

Evidence for Use in Elevated Intraocular Pressure (IOP) and Ocular Hypertension

The research base for the fixed-dose combination (FDC) of Ганфорт includes Phase III Randomized Controlled Trials (RCTs). These short-term, controlled studies examined the FDC in adults diagnosed with Ocular Hypertension (OHT) or Elevated Intraocular Pressure (IOP). Researchers included adult populations who were treatment-naïve and those whose IOP levels met criteria for being inadequately managed by monotherapy. The primary focus was to measure the change in Intraocular Pressure (IOP) from the baseline measurement. IOP was measured as the primary biomarker in these conditions.

The studies reported patterns observed when the combination was evaluated against its individual components. Research highlights changes measured during the short-term study periods, with primary data focusing on observations made at approximately 12 weeks. The High Evidence Level designation aligns with the scientific standard established by multiple, well-controlled comparative trials.

Evidence for Use in Open-Angle Glaucoma (OAG)

The research base for Open-Angle Glaucoma (OAG) also includes Phase III Randomized Controlled Trials comparing the fixed combination to active alternatives. These research scenarios focused on measuring the shift in IOP readings, with studies also monitoring the percentage of patients whose IOP measurements met a specific reduction threshold. Regulatory reviews summarize that the measured IOP values were consistent across the clinical trials when the fixed combination was evaluated.

Duration of Studies and Long-Term Follow-up Data

The core research had limited follow-up durations, with main objectives centered on the measurement of IOP at the 12-week mark. However, long-term effects are not fully established by these initial controlled trials. The characterization of very long-term IOP measurements is less established than the short-term measurements. Definitive findings on the relationship between IOP changes and the long-term preservation of vision rely on broader clinical practice and ongoing observational efforts rather than the primary, short-term research data.

Research in Specific Patient Groups and Evidence Gaps

There is limited information available for certain specialized patient groups. The evidence is constrained to the populations studied and does not fully characterize outcomes for individuals outside of these specific parameters. Comparative evidence is lacking for many other therapeutic combinations, and the data available for the full spectrum of glaucoma severity, particularly for advanced stages of the condition, remains limited. Studies help show what has been observed so far, but the evidence highlights what is known and what is still uncertain across different clinical scenarios.

Frequently Asked Questions (FAQ)

Common questions about Ганфорт (FAQ)

Q: What is the main difference between Ганфорт and other eye drops for glaucoma?

A: According to official product information, Ганфорт is described as a fixed-dose combination of two different active ingredients: bimatoprost (a prostamide) and timolol (a beta-blocker). This combination is intended to use two distinct mechanisms—increasing fluid drainage and reducing fluid production—to help lower intraocular pressure. Other glaucoma drops often rely on only a single active ingredient.

Q: How does the mechanism of action differ from single-ingredient drops?

A: Ганфорт’s formulation contains two substances working simultaneously, offering a dual mechanism of action. One ingredient increases the eye’s natural fluid drainage (bimatoprost), while the other reduces the speed of internal fluid production (timolol). Single-ingredient drops typically utilize only one of these pathways to manage eye pressure.

Q: Can Ганфорт cause a change in eye color?

A: Official documents note the possibility of increased brown iris pigmentation as an observed adverse reaction, classified as uncommon. If this change occurs, official documents state that the darkening of the iris color is considered likely to be permanent.

Q: Are there any long-term consequences of the increased eyelash growth sometimes associated with bimatoprost?

A: Regulatory documents list changes to the length, thickness, or number of eyelashes, as well as the darkening of the eyelid skin, as known local effects. The official safety profile notes that the long-term effects of increased iris pigmentation are not fully established from the initial studies.

Q: Does the research evidence support the use of Ганфорт for all types of glaucoma?

A: The medicine is authorized for the management of elevated pressure in adult patients with open-angle glaucoma or ocular hypertension. Official documents state that the medicine has not been studied for use in certain other types of glaucoma, such as neovascular or angle-closure glaucoma.

Q: What does official data say about the effectiveness of Ганфорт?

A: Official research data for Ганфорт is centered on studies that measure the reduction of intraocular pressure (IOP). Lowering IOP is the therapeutic goal of the medicine.

Q: What evidence exists for the benefits of fixed-combination therapy like Ганфорт?

A: The regulatory documents describe the combination of bimatoprost and timolol as having a synergistic action. This means that the measured combined effect in lowering eye pressure is considered to significantly exceed what each individual ingredient achieves when used separately.

Q: Can people with kidney or liver issues use Ганфорт?

A: Official documents indicate that Ганфорт has not been studied in patients with liver or kidney impairment. Therefore, the medicine is designated for use with caution in individuals with these conditions, as official documents indicate the medicine has not been studied in this population.

Q: Does Ганфорт contain any preservatives?

A: The multi-dose bottle formulation of Ганфорт is described in official documents as a preserved solution. The excipient (inactive ingredient) used as the preservative is benzalkonium chloride.

Q: Is Ганфорт generally safe for long-term use?

A: Regulatory reviews state that the controlled-study population provided data considered sufficient to assess the safety profile of the combination. The long-term safety of the medicine has been evaluated in controlled studies.

Q: Why might a doctor switch a patient from a different medicine to Ганфорт?

A: The medicine is authorized for patients who are described as having an insufficient response to a single-ingredient topical beta-blocker or a prostaglandin analogue alone. This regulatory indication provides the clinical context for initiating the fixed-dose combination therapy.

Q: Can Ганфорт be used to treat other eye conditions besides glaucoma?

A: The approved indications for the medicine are strictly limited to the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The official therapeutic indications for the medicine do not include treating other eye conditions beyond elevated intraocular pressure.

Q: What should I do if my eye pressure is not going down while using Ганфорт?

A: Regulatory information states that if a person believes their condition is not improving while using the drops, they should inform their healthcare professional. The medicine is authorized for daily use to maintain the control of eye pressure.

Q: Can using too much Ганфорт cause more side effects?

A: Official regulatory guidance states that the dose should not exceed one drop daily in the affected eye(s). This limit is in place because the active ingredients can be absorbed into the bloodstream, which may lead to systemic side effects.

Q: What if the eye drops get into my other eye or on my skin?

A: Official documents state that there is a potential for hair growth if the solution repeatedly contacts the skin surface outside of the eye. For this reason, regulatory documents state that the drops should be applied as instructed, and contact with the cheek or other skin areas should be avoided.

Q: Is the eye redness associated with Ганфорт temporary?

A: Ocular hyperaemia (eye redness) is classified as a very common adverse reaction. Official documents note that the occurrence of this redness may be reduced with continued treatment over time.

Q: How does Ганфорт differ from other prostaglandin analogs?

A: Ганфорт is a fixed-dose combination that contains the prostaglandin analogue bimatoprost plus the beta-blocker timolol. The inclusion of the beta-blocker is the primary distinction when compared to single-ingredient prostaglandin analogue drops.

Q: Is there a risk of system-wide side effects from eye drops like Ганфорт?

A: Official documents state that the active ingredients may be absorbed systemically (into the bloodstream) following topical application. Due to this absorption, the same types of systemic adverse reactions as seen with oral beta-blocker medicines may occur.

Q: What is the purpose of the bottle design or dropper tip?

A: Regulatory instructions emphasize the crucial need to avoid contamination of the medicine. The instructions state that the container tip must not touch the eye, eyelids, or any other surfaces during use.

Q: What happens if the drops are used on a non-glaucoma eye?

A: The medicine is indicated for use in eyes with elevated intraocular pressure (open-angle glaucoma or ocular hypertension). The purpose of the medication is specifically to facilitate the reduction of this elevated pressure.

Q: Are there specific age limits mentioned for using Ганфорт?

A: Official documents state the medicine is authorized for use in adults, including the elderly. Its use is not recommended for children and adolescents under 18 years of age because safety and efficacy have not been established in this age group.

Q: How long does the pressure-lowering effect of one application of Ганфорт last?

A: The medicine is prescribed to be used once daily at the same time each day. This dosing schedule reflects the intended duration of the pressure-lowering effect over a full 24-hour period.

How should Ганфорт be stored and disposed of?

The official storage and disposal requirements for Ganfort (Bimatoprost and Timolol maleate) are specific to the product formulation and its stability limits.

Formulation	Required Storage Condition	In-Use Stability Limit
Multi-Dose Bottle	Store below 25°C after opening; keep tightly closed.	Discard 4 weeks after opening.
Single-Dose Containers	Keep in original pouch and carton for protection from light and moisture.	Discard 10 days from first opening of the pouch.

Unopened formulations do not require special temperature conditions. The medicine must be kept out of the sight and reach of children. Unused or expired product must be disposed of according to local pharmaceutical waste programs. Disposal via household waste or wastewater is officially prohibited.

Ганфорт